<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899818</url>
  </required_header>
  <id_info>
    <org_study_id>PICCOLETO2</org_study_id>
    <nct_id>NCT03899818</nct_id>
  </id_info>
  <brief_title>Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment</brief_title>
  <acronym>PICCOLETO II</acronym>
  <official_title>Impiego Del Pallone Medicato Per il Trattamento di Piccoli Vasi Coronarici in Confronto Con Stent Medicato - Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatebenefratelli and Ophthalmic Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fatebenefratelli and Ophthalmic Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentre, randomized clinical study of consecutive patients with
      coronary artery disease in vessels with diameter ≤2.75 mm. Patients will be randomized to
      drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent
      (DES). Study population will consist of 240 patients with stable or unstable angina
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">April 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verify the non-inferiority of DCB</measure>
    <time_frame>up to 6 months</time_frame>
    <description>the primary objective of the study is the non-inferiority of the DCB compared to DES in terms of absence of restenosis, defined as reoccurrence of stenoses of at least 50% of the lumen of the vessel at angiographic follow-up (6 months after surgery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with changes of vessels lumen</measure>
    <time_frame>up to 12 months</time_frame>
    <description>any differences between groups in terms of vascular changes to angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration in blood chemistry</measure>
    <time_frame>up to 6 months</time_frame>
    <description>changes of concentration in blood chemistry between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>appearance of major cardiovascular adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>new generation DEB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>drug-eluting balloon (DEB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>second generation DES</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard therapy with second generation drug-eluting stent (DES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting balloon</intervention_name>
    <description>Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)</description>
    <arm_group_label>new generation DEB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting stent</intervention_name>
    <description>Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).</description>
    <arm_group_label>second generation DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age &gt;18 years.

          2. Stable or unstable coronary artery disease.

          3. Native coronary artery lesion in vessel with diameter &lt;2.75 mm.

          4. Clinical indication to percutaneous coronary intervention (PCI).

        Exclusion criteria

          1. Enrolment in another study with any investigational drug or device.

          2. Acute or recent (≤48 hours) myocardial infarction.

          3. Creatinine clearance &lt;50 ml/min.

          4. Left ventricle ejection fraction &lt;30%.

          5. Any known allergy, hypersensitivity or intolerance to any drug used during or after
             the procedure.

          6. Heavily calcified and severely tortuous lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fatebenefratelli and Ophthalmic Hospital</investigator_affiliation>
    <investigator_full_name>Bernardo Cortese</investigator_full_name>
    <investigator_title>Principal Investigator, A.O. Fatebenefratelli Milano, Italy</investigator_title>
  </responsible_party>
  <keyword>small vessels</keyword>
  <keyword>drug coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

